Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Plozasiran Sales Forecast and Market Size Analysis - 2034 Report Reveals How Quarterly Dosing and Up to 74% Triglyceride Reduction Position Arrowhead's siRNA Across the 7MM

globenewswire.com
ARWR The article discusses plozasiran, a therapy developed by Arrowhead's subsidiary Visirna Therapeutics. While the therapy shows promise in triglyceride reduction and has a differentiated mechanism, the article focuses on a market analysis report and a licensing deal with Sanofi, rather than Arrowhead's direct financial performance or future outlook.

Plozasiran Sales Forecast and Market Size Analysis - 2034 Report Reveals How Quarterly Dosing and Up to 74% Triglyceride Reduction Position Arrowhead's siRNA Across the 7MM Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Plozasiran Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

Research and Markets has published Plozasiran Sales Forecast and Market Size Analysis - 2034, a report released in April 2026. The report assesses the commercial outlook for plozasiran, a first-in-class small interfering RNA (siRNA) therapy targeting apolipoprotein C-III (APOC3). It covers the seven major markets (7MM) over a 2020-2034 study period.

Key Facts

A Differentiated Mechanism in Lipid Lowering

Plozasiran works by silencing hepatic APOC3 mRNA. This improves the clearance of triglyceride-rich lipoproteins. The report notes that genetic and clinical data link APOC3 reduction to lower cardiovascular risk, positioning plozasiran as a next-generation lipid-lowering therapy. Clinical data place it among the most potent triglyceride-lowering therapies reported.

Growth Drivers

The report identifies four factors behind plozasiran's commercial potential:

Indication Strategy

Plozasiran is being developed for severe hypertriglyceridemia (sHTG), familial chylomicronemia syndrome (FCS), and mixed hyperlipidemia. The report says this mix combines an ultra-rare, high-value orphan market (FCS) with large-population indications. That supports both premium pricing and volume-driven growth.

Recent Developments

In August 2025, Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, agreed to sell the exclusive license for plozasiran in Greater China to Sanofi.

Competitive Landscape

The report reviews marketed therapies and late-stage emerging therapies in each indication, including their expected launch dates. It also assesses plozasiran's market positioning, strengths, and weaknesses relative to these competitors.

Report Scope

The report covers:

For more information about this report visit https://www.researchandmarkets.com/r/9nt5j4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.